AP01
September 12, 2023
Nebulised Pirfenidone in Non-Idiopathic Pulmonary Fibrosis (IPF) Progressive Pulmonary Fibrosis (PPF): First Look at FVC Data
West A, Lawrence A, Bao H, et al (2023) poster presented at European Respiratory Society (ERS) International Congress
September 12, 2023
Inhaled pirfenidone (AP01) forced vital capacity (FVC) data from the ATLAS study vs placebo from 3 historical idiopathic pulmonary fibrosis (IPF) randomised controlled trials (RCTs)
Chaudhuri N, Lancaster L, Palmer S, et al. (2023) poster presented at European Respiratory Society (ERS) International Congress
September 12, 2023
Nebulised Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF): First Look at FVC Data
West A, Lawrence A, Bao H, et al. (2023) oral presentation given at European Respiratory Society (ERS) International Congress
May 23, 2023
Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients
Woodhead FA, Nair D, Bao H, et al. (2023) ePoster presented at American Thoracic Society (ATS) International Conference
March 23, 2023
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial
West A, Chaudhuri N, Barczyk A, et al. (2023) Thorax
December 12, 2022
Inhaled Pirfenidone Is Associated With Better Quality of Life Scores in Idiopathic Pulmonary Fibrosis
Kim G, Goldin J, Woodhead F, et al. (2022) European Respiratory Journal
February 6, 2020
Improvement in HRCT Lung Fibrosis With Inhaled Pirfenidone Is Associated With Better Health-Related Quality of Life Scores in Patients With IPF
Woodhead FA, Kim GHJ, Goldin JG, et al. (2022) poster presented at the European Respiratory Society (ERS) International Congress
January 4, 2020
A Randomized Double-Blind Placebo-Controlled Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone
Khoo JK, Montgomery AB, Otto KL, et al. (2018) Journal of Aerosol Medicine and Pulmonary Drug Delivery
December 12, 2019
Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis
Kaminskas LK, Landersdorfer CB, Bischof RJ, et al. (2020) Pharmaceutical Research
February 6, 2018
Pharmacokinetics and Safety of Pirfenidone Following Inhaled Delivery to Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis
Surber M, Kaminskas L, Landersdorfer C, et al. (2019) poster presented at American Thoracic Society (ATS) International Conference
February 5, 2018
Fibroblast–matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype
Shochet GE, Wollin L & Shitrit D. (2018) Asian Pacific Society of Respirology
January 10, 2014
Inhalation Improves Pirfenidone Animal Efficacy Through Superior Pulmonary and Vascular Pharmacokinetics
Surber MW, Poulin D, McInally K, et al. (2014) poster presented at American Thoracic Society (ATS) International Conference
AP02
March 24, 2021
Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
Shochet GE, Bardenstein-Wald B, McElroy M, et al (2021). International Journal of Molecular Science
August 22, 2020
Inhaled Nintedanib Is Well-Tolerated and Delivers Key Pharmacokinetic Parameters Required To Treat Bleomycin-Induced Pulmonary Fibrosis
Surber MW, Beck S, Pham S, et al. (2020) Pulmonary Pharmacology
August 1, 2020
Inhalation: A Means to Explore and Optimize Nintedanib’s Pharmacokinetic/codynamic Relationship
Shochet GE, Pham S, Beck S, et al. (2020) Pulmonary Pharmacology
January 30, 2020
Direct Lung Administration of Nintedanib Reduces Lung Fibrosis in a Multi-Challenge Bleomycin Rat Model
McElroy MC, Beck S, Baily J, et al. (2020) poster presented at American Thoracic Society (ATS) International Conference
February 5, 2018
Fibroblast–matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype
Shochet GE, Wollin L & Shitrit D. (2018) Asian Pacific Society of Respirology
Devices
February 6, 2022
Inhalation: A Means to Improve Existing IPF Therapies
Surber MW, Montgomery AB, Otto K, et al. (2022)
February 6, 2015
Assessment of Regional Lung Deposition of Aerosol Aerodone in IPF Patients Using Functional Respiratory Imaging
Vos W, Van Holsbeke C, Ferreira F, et al. (2015) poster presented at Pulmonary Fibrosis Foundation Summit: From Bench to Bedside